tradingkey.logo

Rhythm Pharmaceuticals Inc

RYTM

89.040USD

+0.040+0.04%
Close 07/10, 16:00ETQuotes delayed by 15 min
5.65BMarket Cap
LossP/E TTM

Rhythm Pharmaceuticals Inc

89.040

+0.040+0.04%
More Details of Rhythm Pharmaceuticals Inc Company
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Company Info
Ticker SymbolRYTM
Company nameRhythm Pharmaceuticals Inc
IPO dateOct 05, 2017
Founded at2013
CEO- -
Number of employees283
Security typeOrdinary Share
Fiscal year-endOct 05
Address222 Berkeley Street
CityBOSTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02116
Phone18572644280
Websitehttps://rhythmtx.com/
Ticker SymbolRYTM
IPO dateOct 05, 2017
Founded at2013
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
+6.36%
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
-0.35%
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
7.00K
+133.33%
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Independent Director
Independent Director
7.00K
+133.33%
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Alastair (Al) Garfield, Ph.D.
Dr. Alastair (Al) Garfield, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
+6.36%
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
-0.35%
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
No Data
By RegionUSD
Name
Revenue
Proportion
United States
96.11M
73.86%
International
34.02M
26.14%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
9.56%
PRIMECAP Management Company
9.10%
Baker Bros. Advisors LP
8.81%
BlackRock Institutional Trust Company, N.A.
6.29%
The Vanguard Group, Inc.
5.40%
Other
60.85%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
9.56%
PRIMECAP Management Company
9.10%
Baker Bros. Advisors LP
8.81%
BlackRock Institutional Trust Company, N.A.
6.29%
The Vanguard Group, Inc.
5.40%
Other
60.85%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
33.95%
Investment Advisor
29.07%
Venture Capital
15.18%
Hedge Fund
14.38%
Private Equity
5.67%
Research Firm
3.79%
Individual Investor
0.70%
Bank and Trust
0.70%
Sovereign Wealth Fund
0.32%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
446
66.23M
104.10%
-6.62M
2025Q1
464
66.24M
104.13%
-6.91M
2024Q4
438
66.17M
104.69%
-7.75M
2024Q3
414
68.98M
112.28%
-7.86M
2024Q2
402
70.62M
115.59%
-5.66M
2024Q1
385
68.75M
112.78%
-8.84M
2023Q4
369
67.33M
113.30%
-8.52M
2023Q3
350
68.72M
116.31%
-2.96M
2023Q2
327
67.69M
118.97%
+564.21K
2023Q1
340
61.98M
109.09%
-8.65M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
6.08M
9.56%
--
--
Mar 31, 2025
PRIMECAP Management Company
5.79M
9.1%
-783.87K
-11.93%
Mar 31, 2025
Baker Bros. Advisors LP
5.60M
8.81%
-479.77K
-7.89%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.00M
6.29%
-64.82K
-1.59%
Mar 31, 2025
The Vanguard Group, Inc.
3.43M
5.4%
+2.33K
+0.07%
Mar 31, 2025
New Enterprise Associates (NEA)
2.91M
4.57%
--
--
Mar 31, 2025
Perceptive Advisors LLC
2.55M
4.01%
-1.13M
-30.76%
Mar 31, 2025
State Street Global Advisors (US)
1.97M
3.1%
+129.86K
+7.05%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.69M
2.66%
-26.51K
-1.54%
Mar 31, 2025
Janus Henderson Investors
1.66M
2.6%
+435.80K
+35.73%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
ALPS Medical Breakthroughs ETF
3.41%
Virtus LifeSci Biotech Products ETF
1.99%
Innovator IBD 50 Fund ETF
1.93%
Harbor Health Care ETF
1.69%
Harbor Human Capital Factor US Small Cap ETF
1.42%
iShares Health Innovation Active ETF
1.19%
SPDR S&P Biotech ETF
0.86%
Federated Hermes MDT Small Cap Core ETF
0.7%
NYLI Healthy Hearts ETF
0.61%
First Trust Small Cap Growth AlphaDEX Fund
0.56%
View more
ALPS Medical Breakthroughs ETF
Proportion3.41%
Virtus LifeSci Biotech Products ETF
Proportion1.99%
Innovator IBD 50 Fund ETF
Proportion1.93%
Harbor Health Care ETF
Proportion1.69%
Harbor Human Capital Factor US Small Cap ETF
Proportion1.42%
iShares Health Innovation Active ETF
Proportion1.19%
SPDR S&P Biotech ETF
Proportion0.86%
Federated Hermes MDT Small Cap Core ETF
Proportion0.7%
NYLI Healthy Hearts ETF
Proportion0.61%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.56%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI